Skip to main content

Table 2 Percentage of treatment-related adverse events

From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Adverse event Percentage
Fatigue 6.4
Diarrhea 5.1
Constipation 4.5
Insomnia 4.5
Vomiting 2.9
Anemia 2.6
Headache 2.6
Dizziness 2.3
Dyspnea 2.3
Rash 2.3
\